Antibody responsive malignanacy
Drug safety update
December 2014: Rituximab: progressive multifocal leukoencephalopathy in a patient
December 2014: Rituximab: screen for hepatitis B virus before treatment
Nice guidance (also see drug specific guidance below)
NG52: Non-Hodgkin’s lymphoma: diagnosis and management, July 2016Rituximab causes the lysis of B lymphocytes and may be used to treat rheumatoid arthritis when therapy with other DMARDs including one anti-TNF has been inadequate or not tolerated.
Systemic Anti-Cancer Therapy (SACT) guidance including pathways for managing complications and adverse events directly linked to SACT which may present both in emergency departments and on the general wards. This covers both chemotherapy and immune related toxicities.
| Pack | Price |
|---|---|
| 2 vial | £349.25 |
| Pack | Price |
|---|---|
| 1 vial | £873.15 |